Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.

PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

Personalized sonidegib dosing can effectively treat Gorlin-Goltz syndrome with fewer side effects.

Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Ruxolitinib can help regrow hair in severe alopecia areata.

Deleting Smad4 and PTEN genes in mice causes rapid, invasive forestomach cancer.

Upadacitinib effectively treats psoriasis and lichen planus together.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Uveal melanoma is hard to treat when it spreads, but a new drug, tebentafusp, helps patients live longer.

Drugs targeting EMT molecules show promise for treating lichen planopilaris.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Erlotinib can cause excessive eyelash growth.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

EGFR-TKIs can cause unexpected skin, nail, and hair issues.

Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.

Tolvaptan can slow kidney disease progression, but doesn't affect mortality or kidney failure.